RCKTW — ROCKET PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1281895 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -48,511,000 | -47,594,000 | 285,407,000 | 49,610,000 | 47,368,000 |
| Dec 2025 | 0 | — | -44,031,000 | -42,538,000 | 330,449,000 | 77,558,000 | 53,228,000 |
| Sep 2025 | 0 | — | -52,419,000 | -50,332,000 | 368,033,000 | 75,948,000 | 54,364,000 |
| Jun 2025 | 0 | — | -67,678,000 | -68,919,000 | 420,979,000 | 32,819,000 | 66,768,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-190,014,000
Investing CF
$103,767,000
Financing CF
$148,000
CapEx
$-803,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
—
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,441,239,000
Inventory
—
Receivables
—
ST Investments
$111,371,000
EBIT TTM
$-221,232,000
Pretax Income TTM
$-223,123,000
Interest Exp TTM
$1,891,000
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -228,516,000 | -223,123,000 | 330,449,000 | 53,228,000 | — | -190,014,000 |
| Dec 2024 | 0 | -273,205,000 | -258,746,000 | 527,700,000 | 64,466,000 | — | -209,724,000 |
| Dec 2023 | 0 | -259,659,000 | -245,595,000 | 566,341,000 | 73,767,000 | — | -194,916,000 |
| Dec 2022 | 0 | -223,843,000 | -221,863,000 | 551,807,000 | 62,121,000 | — | -178,142,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.06T | $1188.58 | — |
| JNJ | JOHNSON & JOHNSON | $618.61B | $256.98 | — |
| ABBV | AbbVie Inc. | $438.31B | $248.08 | — |
| NVSEF | NOVARTIS AG | $305.29B | $160.00 | — |
| MRK | Merck & Co., Inc. | $305.12B | $123.54 | — |
News headlines (Yahoo Finance, 1h cache)
Is Rocket Pharmaceuticals, Inc. (RCKT) Poised for Recovery After Key Gene Therapy Program Milestone?
2026-06-25 12:42 · Yahoo
Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
2026-06-12 11:00 · Yahoo
Rocket Pharmaceuticals Inc (RCKT) Got Cash. Where’s the Stock Going?
2026-05-20 12:35 · Yahoo
Rocket Pharmaceuticals (RCKT) Reports Q1 2026 Net Loss of $47.6M
2026-05-18 04:50 · Yahoo
RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus
2026-05-11 15:50 · Yahoo
Rocket Pharmaceuticals' Cardiac Programs Updates to Offer 'Strong' Share Price Catalysts, Wedbush Says
2026-05-08 16:18 · Yahoo
Rocket to sell PRV for $180m to advance gene therapy pipeline
2026-04-29 09:34 · Yahoo
RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease
2026-03-30 16:16 · Yahoo
Why Rocket Pharmaceuticals (RCKT) Got a Commercial Boost From FDA Approval of KRESLADI
2026-03-29 20:54 · Yahoo
Rocket Pharmaceuticals (RCKT) Is Down 8.9% After FDA Accelerated Approval Of KRESLADI Gene Therapy
2026-03-29 17:03 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.